Who are we?
Biotis is a dynamic company in the Israeli Bio-Pharmaceutical industry, dedicated to representing international pharmaceutical partners and premium ethical products approved in Europe and or USA.
Biotis offers a full range of professional services from regulatory approvals, comprehensive strategic marketing, import, sales and distribution of ethical drugs and other medications.
Who we are
- Founded in 2006, Biotis is a dynamic, medium sized company in the Israeli bio-pharma industry, dedicated to providing international pharmaceutical partners with a full range of professional services for the local market.
- Biotis partnership options range from regulatory approvals, comprehensive strategic marketing, import, sales and distribution of premium ethical drugs and high quality generic products.
- Biotis is part of the Shizim Group of companies that also includes GCP Clinical Studies Ltd., a leading provider of clinical research services for pharmaceutical companies, training and certification of healthcare professionals involved in the conduct of clinical trials
Drugs Disributed by Biotis Ltd
Macrolide. Erythromycin 1 g/vial. VIAL: 1 x 1 g. 15-20 mg/kg/day. Severe
infects: Up to 4 g.
Bact. infects. req. I.V. tmt.
C/I: Hypersens. to erythromycin.
See lit.
Selective α1 Blocker. Terazosin (as monohydrochloride dihydrate) 2 mg. TABS: Starter Pack: 7 x 1 mg, 2 mg. 28 x 5 mg, 10 mg. Initial: 1 x 1 mg tab 1 x
dly at bedt. Incr. step-wise to 2 mg, 5 mg
or 10 mg 1 x dly to achieve desired
effect.
Sympt. tmt. urinary obstruct. caused by
BPH, mild to mod. hypertens.